Alector, Inc. (ALEC)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$78.8M
Cash & Equivalents
$49.8M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$245M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07105709 Open-label Extension Study in Participants With Early Alzheimer's Disease PHASE2 Recruiting 220
NCT06079190 Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease PHASE2 Active Not Recruiting 367

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ALEC.

SEC EDGAR Filings

All SEC filings for Alector, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.